These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 2606579

  • 1. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors.
    Belardelli F, Ciolli V, Testa U, Montesoro E, Bulgarini D, Proietti E, Borghi P, Sestili P, Locardi C, Peschle C.
    Int J Cancer; 1989 Dec 15; 44(6):1108-16. PubMed ID: 2606579
    [Abstract] [Full Text] [Related]

  • 2. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.
    Ciolli V, Gabriele L, Sestili P, Varano F, Proietti E, Gresser I, Testa U, Montesoro E, Bulgarini D, Mariani G.
    J Exp Med; 1991 Feb 01; 173(2):313-22. PubMed ID: 1671080
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
    Ferrantini M, Proietti E, Santodonato L, Gabriele L, Peretti M, Plavec I, Meyer F, Kaido T, Gresser I, Belardelli F.
    Cancer Res; 1993 Mar 01; 53(5):1107-12. PubMed ID: 8439955
    [Abstract] [Full Text] [Related]

  • 5. Synergistic anti-tumor effects of combined IL-1/IFN-alpha/beta therapy in mice injected with metastatic Friend erythroleukemia cells.
    Belardelli F, Gabriele L, Proietti E, Sestili P, Peretti M, Rozera C, Gresser I.
    Int J Cancer; 1991 Sep 09; 49(2):274-8. PubMed ID: 1879971
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN alpha/beta therapy of Friend erythroleukemia visceral metastases.
    Kaido T, Gresser I, Maury C, Maunoury MT, Vignaux F, Belardelli F.
    Int J Cancer; 1993 May 28; 54(3):475-81. PubMed ID: 8509222
    [Abstract] [Full Text] [Related]

  • 8. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD.
    Surgery; 1990 Nov 28; 108(5):919-29. PubMed ID: 2237773
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effect of interleukin-1 beta in the double grafted tumor system.
    Ebina T, Ishikawa K.
    Jpn J Cancer Res; 1989 Jun 28; 80(6):570-6. PubMed ID: 2503477
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action.
    Sala A, Gresser I, Chassoux D, Maury C, Santodonato L, Eid P, Maunoury MT, Barca S, Cianfriglia M, Belardelli F.
    Cancer Res; 1992 May 15; 52(10):2880-9. PubMed ID: 1581903
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F.
    J Clin Invest; 1998 Jan 15; 101(2):429-41. PubMed ID: 9435316
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN, Khoo NK, Lala PK.
    Cancer Res; 1992 Dec 01; 52(23):6452-62. PubMed ID: 1423293
    [Abstract] [Full Text] [Related]

  • 16. Enhanced activity against syngeneic murine tumors by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1).
    Nakajima I, Ozaki M, Jinnai H, Shilayama Y, Hirohata T, Okuno K, Yasutomi M.
    Cancer Biother; 1993 Dec 01; 8(4):319-26. PubMed ID: 7804373
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR, Klarnet JP, Peace DJ, Cheever MA, Badger CC, Bernstein ID, Greenberg PD.
    Cancer Res; 1990 Sep 01; 50(17):5421-5. PubMed ID: 2386946
    [Abstract] [Full Text] [Related]

  • 18. Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize.
    Belardelli F, Ferrantini M, Maury C, Santurbano L, Gresser I.
    Int J Cancer; 1984 Sep 15; 34(3):389-95. PubMed ID: 6207117
    [Abstract] [Full Text] [Related]

  • 19. [Injection of interleukin-2 (IL-2) into the tumor-bearer's spleen augments lymphokine-activated killer (LAK) activity in vitro and inhibits tumor metastasis].
    Okuno K, Ohnishi H, Takagi H, Nakamura T, Kokudo S, Yasutomi M.
    Nihon Geka Gakkai Zasshi; 1987 Jul 15; 88(7):802-7. PubMed ID: 3499562
    [Abstract] [Full Text] [Related]

  • 20. Correlation between the sensitivity or resistance to IL-2 and the response to cyclophosphamide of 4 tumors transplantable in the same murine host.
    Greco G, Gabriele L, Rozera C, Venditti M, Belardelli F, Proietti E.
    Int J Cancer; 1995 Jul 17; 62(2):184-90. PubMed ID: 7622294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.